Chimeric antigen receptor T-cell (CAR T-cell) therapy is a process developed to treat certain forms of cancers, especially blood cancers like leukemia and lymphoma. Recently, however, researchers have started exploring its use for autoimmune diseases, including idiopathic inflammatory myositis (IIM). This application is still experimental and not yet available for myositis outside of research studies,…
Continue Reading
TMA was honored to partner with Myositis Support and Understanding (MSU) to host the Externally Led Patient Focused Drug Development (PFDD) meeting for adult dermatomyositis (DM) on June 7. View the replay of this important day online. Through the PFDD, we captured DM patients’ experience, perspectives, and needs. The program was designed to inform the…
Continue Reading
TMA’s top 10 travel tips help you achieve those bucket-list wishes, including making the most of our International Annual Patient Conference.
Continue Reading
The first-ever Externally Led Patient Focused Drug Development (EL-PFDD) meeting on June 7 offered a critical way for patients and their family members to highlight what life with DM is like.
Continue Reading
TMA medical advisor and patient advocate Ingrid de Groot insists patients be involved in medical research.
Continue Reading